ChondroCelect

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
12-01-2017
Tabia za bidhaa Tabia za bidhaa (SPC)
12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma (PAR)
12-01-2017

Viambatanisho vya kazi:

characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

Inapatikana kutoka:

TiGenix N.V.

ATC kanuni:

M09AX02

INN (Jina la Kimataifa):

characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

Kundi la matibabu:

Other drugs for disorders of the musculo-skeletal system

Eneo la matibabu:

Cartilage Diseases

Matibabu dalili:

Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults.Concomitant asymptomatic cartilage lesions (ICRS grade I or II) might be present. Demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of Chondrocelect in patients with lesions between 1 and 5 cm².

Bidhaa muhtasari:

Revision: 6

Idhini hali ya:

Withdrawn

Idhini ya tarehe:

2009-10-05

Taarifa za kipeperushi

                                20
B. PACKAGE LEAFLET
Medicinal product no longer authorised
21
PACKAGE LEAFLET: INFORMATION FOR THE USER
_ _
CHONDROCELECT 10,000 CELLS/MICROLITRE IMPLANTATION SUSPENSION
Characterised viable autologous cartilage cells expanded
_ex vivo_
expressing specific marker proteins
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, surgeon or
physical therapist.
-
If you get any of the side effects, talk to your doctor, surgeon or
physical therapist. This
includes any possible side effects not listed in this leaflet. See
section 4.
WHAT IS IN THIS LEAFLET
1.
What ChondroCelect is and what it is used for
2.
What you need to know before you use ChondroCelect
3.
How to use ChondroCelect
4.
Possible side effects
5.
How to store ChondroCelect
6.
Contents of the pack and other information
1.
WHAT CHONDROCELECT IS AND WHAT IT IS USED FOR
ChondroCelect consists of autologous cultured cartilage cells. The
product is made from a small
sample of cartilage cells (a biopsy) taken from your knee.
•
AUTOLOGOUS
means that your own cells are used to make ChondroCelect.
•
CARTILAGE
is a tissue that is present in every joint. It protects the ends of
our bones and allows our
joints to function smoothly.
ChondroCelect is used to repair single symptomatic cartilage defects
in the femoral condyle of the
knee in adults. A defect can be caused by acute trauma, such as a
fall. It can also be caused by
repetitive trauma, as a result of overweight or due to incorrect
weight-bearing on the knee as a result
of a knee deformity.
•
The FEMORAL CONDYLE
is the end of the thigh bone, which forms part of your knee.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE CHONDROCELECT
_ _
DO NOT USE CHONDROCELECT IF YOU:
-
are allergic to any of the ingredients of ChondroCelect (listed in
section 6) or to bovine serum
-
suffer from advanced osteoarthritis (degenerative joint disease) in
your 
                                
                                Soma hati kamili

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
_ _
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
ChondroCelect 10,000 cells/microlitre implantation suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
2.1
GENERAL DESCRIPTION
Characterised viable autologous cartilage cells expanded
_ex vivo_
expressing specific marker proteins.
2.2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial of product contains 4 million autologous human cartilage
cells in 0.4 ml cell suspension,
corresponding to a concentration of 10,000 cells/microlitre.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Implantation suspension
Before re-suspension the cells are settled to the bottom of the
container forming an off-white layer and
the excipient is a clear colourless liquid.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Repair of single symptomatic cartilage defects of the femoral condyle
of the knee (International
Cartilage Repair Society [ICRS] grade III or IV) in adults.
Concomitant asymptomatic cartilage
lesions (ICRS grade I or II) might be present. Demonstration of
efficacy is based on a randomised
controlled trial evaluating the efficacy of Chondrocelect in patients
with lesions between 1-5cm².
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
ChondroCelect must be administered by an appropriately qualified
surgeon and is restricted to hospital
use only. ChondroCelect is solely intended for autologous use and
should be administered in
conjunction with debridement (preparation of the defect bed), a
physical seal of the lesion (placement
of a biological membrane, preferentially a collagen membrane) and
rehabilitation.
Posology
The amount of cells to be administered is dependent on the size
(surface in cm²) of the cartilage defect.
Each product contains an individual treatment dose with sufficient
number of cells to treat the pre-
defined lesion size, as measured at biopsy procurement. The
recommended dose of ChondroCelect is
0.8 to 1 million cells/cm², corresponding with 80 to 100 mic
                                
                                Soma hati kamili

Bidhaa zinazofanana

Viambatanisho vya kazi characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

ATC kanuni M09AX02

M09AX02

Mzalishaji au wazalishaji wadogowadogo TiGenix N.V.

TiGenix N.V.

INN (Jina la Kimataifa) characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kibulgaria 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kihispania 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kicheki 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kidenmaki 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kijerumani 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kiestonia 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kigiriki 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kifaransa 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kiitaliano 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kilatvia 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kilithuania 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kihungari 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kimalta 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kiholanzi 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kipolandi 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kireno 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kiromania 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kislovakia 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kislovenia 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kifinlandi 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kiswidi 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kinorwe 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 12-01-2017
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 12-01-2017
Tabia za bidhaa Tabia za bidhaa Kroeshia 12-01-2017
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 12-01-2017

Tafuta arifu zinazohusiana na bidhaa hii

Taadhari ChondroCelect characterised viable autologous cartilage cells expanded vivo expressing

ChondroCelect characterised viable autologous cartilage cells expanded vivo expressing

Tazama historia ya hati

Historia ya nyaraka Historia ya nyaraka

ChondroCelect